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ABSTRACT
Residual androgen receptor (AR)-signaling and presence of cancer stem-like 
cells (SCs) are the two emerging paradigms for clinically challenging castration-
resistant prostate cancer (CRPC). Therefore, identification of AR-target proteins that 
are also overexpressed in the cancer SC population would be an attractive therapeutic 
approach. 
Our analysis of over three hundred clinical samples and patient-derived prostate 
epithelial cultures (PPECs), revealed Cancerous inhibitor of protein phosphatase 2A 
(CIP2A) as one such target. CIP2A is significantly overexpressed in both hormone-
naïve prostate cancer (HN-PC) and CRPC patients . CIP2A is also overexpressed, 
by 3- and 30-fold, in HN-PC and CRPC SCs respectively. In vivo binding of the AR to 
the intronic region of CIP2A and its functionality in the AR-moderate and AR-high 
expressing LNCaP cell-model systems is also demonstrated. Further, we show that AR 
positively regulates CIP2A expression, both at the mRNA and protein level. Finally, 
CIP2A depletion reduced cell viability and colony forming efficiency of AR-independent 
PPECs as well as AR-responsive LNCaP cells, in which anchorage-independent growth 
is also impaired.
These findings identify CIP2A as a common denominator for AR-signaling and 
cancer SC functionality, highlighting its potential therapeutic significance in the most 
clinically challenging prostate pathology: castration-resistant prostate cancer.
INTRODUCTION
Since AR is instrumental in the progression of 
prostate cancer (PC) [1], it has been the main focus 
of therapeutics. Androgen ablation, either chemical 
or surgical, has been the mainstay of treatment for 
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advanced PC. However due to subsequent resistance to 
androgen ablation, this approach fails to achieve a cure. 
The resulting recurrent tumors are commonly known 
as castration-resistant prostate cancers (CRPCs). It has 
now been demonstrated that these cells remain androgen 
sensitive [2]. One third of the CRPCs harbor amplification 
of the AR gene [1] . In addition, rearrangements of AR, 
resulting in ligand independent activation of the receptor 
has been reported [2]. Also, in antiandrogen treated 
tumors, point mutations abrogating the effect of the drugs 
have been identified [3] and it has been shown that CRPC 
cells can produce low levels of androgens endogenously 
[4]. These adaptations make CRPCs responsive to 
the second line AR-signaling blocking drugs, such as 
abiraterone and enzalutamide. But even these second 
line drugs are effective only in a proportion of patients 
and fail to completely cure responsive patients [5]. On 
the other hand, the existence of cancer stem cells (SCs) 
in advanced stage PC and CRPCs has been suggested as 
another potential mechanism for resistance to drugs [6]. 
Several recent studies have suggested that cancer SCs 
are androgen-independent [7, 8]. Together these results 
indicate that efficient therapy for advanced stage PC would 
require simultaneous targeting of two types of cancer cell 
populations: those that are dependent on AR-signaling 
and the AR-independent (cells that are non-responsive to 
androgens) cancer stem-like cells. 
CIP2A, an endogenous inhibitor of protein 
phosphatase 2A (PP2A), is a recently identified oncogene, 
which is overexpressed in several tumour types at a 
very high frequency [9-14]. In fact, its overexpression 
is emerging as one of the most frequent alterations in 
human cancers [13]. MYC, E2F1, AKT and mTOR have 
so far been identified as downstream oncogenic effectors 
of CIP2A [13, 15]. The clinical relevance of CIP2A, in 
the form of a prognostic marker, has been established 
for different human cancers [13]. Notably, in a study 
involving small number of cases, CIP2A overexpression 
was observed in hormone-naïve prostate cancer (HN-
PC) specimens and its expression was associated with 
poorly differentiated and high-risk PCs [16]. However, its 
functional role in prostate cancer cell biology still remains 
elusive.
RESULTS
To study the role of CIP2A in prostate cancer, we 
first investigated the expression and androgen regulation 
of this gene in clinical tissue samples, prostate cancer cell 
lines and different cell populations from benign prostate 
hypertrophy (BPH), HN-PC and CRPC patient samples. 
CIP2A was overexpressed in HN-PC and even more 
in CRPC compared to BPH at the mRNA level (Figure 
1A). Also immunostaining showed higher protein levels 
in CRPC compared to HN-PC (Figure 1B, 1C). Notably, 
99% of CRPC patient samples were positive for CIP2A 
expression (Figure 1C). CIP2A protein expression was 
also demonstrated in AR-positive PC cell lines (Figure 
1D). 
Next, we assessed the expression of CIP2A in the 
different populations of cells from biopsy samples of BPH, 
HN-PC and CRPC patients. We isolated the stem-like 
cell (SC), transient amplifying cell (TA) and committed 
basal cell (CB) populations using CD133, CD44 and α2β1 
cell surface markers as shown in Figure S1A. We have 
previously demonstrated that primary HN-PC tissue 
and SC cells form serially transplantable subcutaneous 
tumors in Rag2-/-γC-/- immune compromised mice, which 
can form distant metastasis and multiple intraprostatic 
tumors in nude mice when grafted orthotopically in a 
matrigel plug containing human prostatic stroma [17]. 
As shown in Figure 2A, the expression of CIP2A in the 
cancer stem-like cell (SC) population, was increased by 
about three-fold in HN-PC-SCs and by about thirty-fold 
in CRPC-SCs compared to BPH-SCs. In contrast, CIP2A 
expression was decreased in TA and CB cell populations 
in cancer (Figure S1B, S1C). Functionally, depletion 
of CIP2A in the primary HN-PC PPECs cells with two 
different siRNAs (Figure 2B) resulted in decrease in both 
cell viability (Figure 2C) and colony forming capacity 
(Figure 2D). Particularly, the colony forming capacity in 
the BPH PPECs was not significantly altered on CIP2A 
depletion (Figure 2D). Together these results indicate that 
CIP2A is important for the survival of HN-PC stem-like 
cell (SC) populations.
Having confirmed functional significance, we 
next investigated the regulation of CIP2A expression. 
Although, overexpression and a functional significance 
of CIP2A in androgen-independent cancer SCs implied 
AR-independent effects of CIP2A, we also have strong 
evidence for AR-mediated CIP2A regulation in AR-
responsive cells. A statistically significant association of 
CIP2A immunopositivity with AR nuclear staining was 
observed in primary HN-PC samples (Figure S2A;[18]). 
ChIP-Seq data in prostate cancer cell lines from previously 
published studies revealed an AR binding site in CIP2A 
intronic region (Figure S2B). The in vivo functionality of 
this site was demonstrated by an increase in AR binding 
at this locus upon dihydrotestosterone (DHT) induction in 
LNCaP cells using ChIP-qPCR (Figure 3A). The LNCaP 
cells modified to expressed 2-4 (ARmo) and 6- (ARhi) 
fold higher levels of AR compared to control (pcDNA3.1) 
LNCaP cells [19] showed stronger binding (Figure 3A) 
upon DHT treatment. In addition, an increase in CIP2A 
mRNA expression was seen in LNCaP-ARhi compared to 
LNCaP-pcDNA3.1 cells after treatment with even modest 
doses of DHT (Figure 3B and S3A). Similarly, higher 
CIP2A protein levels were observed in LNCaP-ARhi 
cells in comparison to LNCaP-pcDNA3.1 cells with low 
DHT stimulation (Figure 3C). Also, immunofluorescene 
staining demonstrated higher CIP2A protein levels in 
LNCaP-ARhi compared to LNCaP-pcDNA3.1 cells after 
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1nM DHT (24h) treatment (Figure S3B). These findings 
are in line with our previous observations that androgen-
regulated genes are induced in cells overexpressing 
AR, even in lower ligand concentrations [19]. Next, an 
independent siRNA based approach to verify the role of 
androgen receptor in CIP2A regulation was used. We 
transfected two known AR-positive prostate cancer cell 
lines, LNCaP and VCaP (Figure 3D), with siRNAs against 
AR and estimated the CIP2A protein levels. As shown in 
Figure 3D, AR depletion resulted in decreased CIP2A 
protein expression in both the AR-positive prostate cancer 
cell lines.
To assess whether the AR-mediated positive 
regulation of CIP2A expression has any functional 
consequence, we transfected LNCaP-pcDNA3.1 and 
LNCaP-ARhi cells with CIP2A siRNAs and performed the 
functional assays. As demonstrated in Figure 4A, about 4 
to 5 fold decrease in cell viability was observed in both 
LNCaP-pcDNA3.1 and LNCaP-ARhi cells. Further, we 
demonstrated that CIP2A promotes clonogenicity (Figure 
4B) and cellular transformation potential (Figure 4C) 
of LNCaP-pcDNA3.1 and -ARhi cells using monolayer 
clonogenic and anchorage-independent soft agar assays, 
respectively. These functional studies clearly identify 
AR as an upstream regulator of CIP2A, which in turn 
positively modulates cell survival.
Figure 1: CIP2A is overexpressed in prostate cancer. A. Overexpression of CIP2A mRNA in castration resistant prostate cancer 
(CRPC; n = 15) hormone-naïve primary prostate cancer (HN-PC; n = 27) compared to benign prostatic hyperplasia (BPH; n = 8). * =  n 
< 0.05, ***  =  p value  < 0.001 using the Kruskal-Wallis test with Dunn’s multiple comparison post-test. B. CIP2A protein expression in 
prostate cancer specimens as detected by immunohistochemistry. A score of 0 (negative), 1 (weak), 2 (moderate) and 3 (high) was given 
based on the cytoplasmic CIP2A immunopositivity. C. Statistical analysis of CIP2A immunopositivity in both HN-PC and CRPC cases. D. 
Western blot showing CIP2A protein levels in benign and malignant prostate cancer (PC) cells. 
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DISCUSSION
Overexpression of AR has been commonly observed 
not only in primary PCs but also in CRPC cases [1, 2, 
4]. Its role in sensitizing tumor cells to low levels of 
androgens has been a critical deterrent for effective 
therapies in prostate cancer. Additionally, presence 
of cancer stem cells adds another layer of complexity 
for effective treatment, especially in CRPC cases [6]. 
Therefore, new therapeutic approaches that overcome 
these hurdles are urgently required for an effective long-
term therapy against prostate cancer. This can be achieved 
by either using drug combinations that target AR-signaling 
and cancer SC-signaling simultaneously, or by identifying 
and targeting effector proteins common to these signaling 
cascades.
 In this study using patient-derived prostate epithelial 
cultures (PPECs) and over three hundred clinical samples, 
we identify CIP2A to be a common denominator for AR 
and cancer SC-signaling functionality. We demonstrate 
that CIP2A is overexpressed in PC and CRPC cases and 
promotes the viability and clonogenicity of AR-responsive 
prostate cancer cells. Notably, the difference in growth in 
the LNCaP-pcDNA3.1 and LNCaP-ARhi cells was not 
clearly apparent while doing the siRNA based functional 
assays (Figure 4A-4C) despite different AR levels in these 
two populations. This could be either be due to blunting 
of the induction of CIP2A protein levels in ARhi cells 
compared to the parental LNCaP cells (1.6 fold V’s 3.4 
fold) as shown in Figure 3C, or due to usage of normal 
serum medium to carry out the knock-down assays as the 
Figure 2: CIP2A is overexpressed and promotes growth and viability of cancer stem-like cell (SC) population from 
patient-derived prostate epithelial cell (PPECs) cultures. A. Overexpression of CIP2A mRNA in the stem-like cell (SC) population 
of both primary HN-PC and CRPC patient samples in comparison to BPH samples. Note the y-axis scale change between HN-PC and 
CRPC panels. B. Western blot showing the effect of two different CIP2A siRNAs on CIP2A protein levels in primary HN-PC-SC cells in 
comparison to the Scrambled (Scr.) or control transfected cells. C. Effect of CIP2A depletion, using two different siRNAs against CIP2A, 
on cell viability of HN-PC-SC cells from patients in comparison to the control/Scr. transfected cells at 3 and 6 day time point. ( *  =  p-value 
< 0.05 using student t-test) D. Effect of CIP2A depletion on colony forming capacity of primary cells from BPH and HN-PC patients (total 
cell populations) in comparison to the control/Scr. transfected cells expressed as 100% for each. Shown are the effects on both small (less 
than 32 cells) and big colonies (more than 32 cells ; *  =  p-value  < 0.05 using student t-test)
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stress on the cells, due to the combination of transfection 
reagent and presence of stripped medium or low DHT 
conditions, is toxic for the cells. Further, we highlighted 
the role of CIP2A protein in promoting the survival of the 
PC stem-like cell (SC) populations. Importantly, several 
recent studies have demonstrated the tumor suppressive 
role of PP2A complex in prostate cancer [20-22]. Based 
on these findings, we suggest therapeutic targeting of 
CIP2A, an established endogenous inhibitor of PP2A [10, 
11, 14] as a novel approach to simultaneous target both 
the luminal type mass of prostate cancer, as well as the 
tumor initiating capacity of the SC populations (Figure 
4D). However, additional mouse pre-clinical studies are 
required to further strengthen CIP2A’s role in therapy 
against prostate cancer.
Altogether, as CIP2A depletion in many other 
cancer models have been demonstrated to result in 
robust antitumor effects [13, 23] and inhibition of 
activity of several oncogenic driver pathways [13, 15, 
23], these novel results highlight the potential remedial 
role of CIP2A in the more resistant and therapeutically 
challenging prostate cancer cases.
MATERIALS AND METHODS
Clinical samples for mRNA expression
Freshly frozen primary prostate cancer samples 
from prostatectomies (8 BPH and 27 untreated or HNPC 
in addition to 15 CRPC specimens from transurethral 
resection of the prostate-treated patients) were used in the 
study. The samples were snap frozen in liquid nitrogen and 
total RNA was isolated with Trizol-Reagent (Invitrogen 
Inc.) according to the manufacturer’s instructions. Tumor 
samples contained, at least, 70% cancer cells. The use 
of the clinical material has been approved by the ethical 
committee of the Tampere University Hospital. 
Figure 3: Androgen receptor (AR) binds to CIP2A and its activity and expression positively regulates CIP2A expression 
in prostate cancer. A. AR binding on CIP2A intronic region. ChIP-qPCR on LNCaP-pcDNA3.1, -ARmo, -ARhi cells, hormone starved 
for 4 days followed by treatment with 1nM and 100nM DHT for 2h or Ethanol was performed to assess the AR recruitment on the CIP2A 
intronic region. B. Effect on CIP2A mRNA expression in LNCaP-pcDNA3.1, -ARhi cells on DHT (1nM, 10nM, 100nM) stimulation at 
24h time point. C. Effect on CIP2A protein expression in LNCaP-pcDNA3.1, -ARhi cells on DHT (1nM) stimulation at 24h time point 
according to Western blotting. D. Effect of two independent AR siRNAs on CIP2A and AR protein expression in LNCaP cells 72h post-
transfection and effect of AR and CIP2A siRNAs on CIP2A and AR protein expression in VCaP cells 72h post-transfection.
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Figure 4: CIP2A promotes viability, clonogenicity and transformation potential of AR-positive prostate cancer cell 
lines. A. Effect of two independent CIP2A siRNAs on cell viability of LNCaP-pcDNA3.1, -ARhi cells 3 and 6 days post-transfection. 
Student’s t-test was used to obtain the p values. B. Effect of CIP2A siRNA on clonogenicity of LNCaP cells 6 days post-transfection. 
Student’s t-test was used to obtain the p values. C. Effect of two different CIP2A siRNAs on anchorage-independent growth. Here, LNCaP 
cells were transfected with CIP2A.1, CIP2A.2 or Scr. siRNA and, at 48 hours post transfection, plated at low density in soft agar medium. 
Student’s t-test was used to obtain the p values. D. Schematic representation of the therapeutic potential of targeting CIP2A. Since CIP2A 
positivity is common to both AR-dependent and cancer SC populations of prostate cancer, it surfaces as an attractive therapeutic target, 
especially in clinically challenging castration-resistant prostate cancers.
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Tissue microarrays (TMAs)
Tissue microarrays contained 185 formalin-
fixed paraffin-embedded prostatectomy and 92 CRPC 
(transurethral resection of the prostate) specimens obtained 
from Tampere University Hospital. For the prostatectomy-
treated patients, detectable PSA values ≥0.5 ng/ml) in two 
consecutive measurements or the emergence of metastasis 
were considered as signs of progression. The use of tissue 
microarrays has been approved by the ethical committee 
of Tampere University Hospital and the National Authority 
for Medicolegal Affairs. CIP2A immunopositivity was 
graded in one to three tumour cores for each patient based 
on the intensity of the cytoplasmic immunoreactivity in the 
cancer cells, that is, 3 was strong, 2 moderate, 1 weak, and 
0 negative. All samples were scored by, an experienced 
uropathologist (T. Tolonen), without knowledge of clinical 
status and outcome data.
Establishment of primary prostate epithelial 
cultures and enrichment of prostate epithelial 
sub-populations
The epithelial cultures from primary prostate 
samples were established according to an established 
protocol [24]. The postoperative prostate samples were 
obtained with full ethical consent and were chopped 
into fine pieces, which were then subjected to overnight 
collagenase (Lorne Laboratories) treatment at 37oC. Then, 
the stroma was separated by differential centrifugation 
and prostate epithelial acini were further disrupted by 
mechanical and enzymatic separation methods. At this 
point, CD24 positive luminal cells were removed and 
enriched by employing CD24 MACS immunomagnetic 
beads (Miltenyi Biotec). The rest of the prostate epithelial 
cells were then grown with irradiated STOs on collagen 
I coated plastic plates in a stem cell media at 37oC with 
5% CO2. Cells were sub-cultured typically when they 
were 80-90% confluent by splitting them into 1:3 or 1:4 
proportions. At passage two; cultured epithelial cells were 
selected on the basis of expression of α2β1-integrin, CD44, 
and CD133 expression by employing rapid collagen 
adhesion and CD133 MACS fractionation (Figure S1A). 
Cell lines and cell culture
LNCaP cells were purchased from American Type 
Culture Collection (ATCC) and well established LNCaP-
pcDNA3.1, LNCaP-ARmo and LNCaP-ARhi sub cell 
lines [19] expressing low (endogenous AR levels), 
moderate (two to four fold) and high AR (four to six fold) 
AR expression (26) respectively were also grown as per 
the recommended conditions. VCaP cells used were a kind 
gift by Dr. Jack Schalken- Radboud University, Nijmegen 
Medical Center, and were grown under the recommended 
conditions. With respect to primary cells prostate cancer 
directed core biopsies from three HN-PC patients had 
Gleason score of 4+3 while CRPCs were Gleason 9 (4+5, 
one sample) and 10 (5+5, 2 samples) were processed to 
establish cultures in stem cell medium (SCM) as described 
before [24]. 
Quantitative (q) RT-PCR
Cells were collected from dishes and their total RNA 
was extracted using Trizol (Invitrogen) according to the 
manufacturer’s instructions. First-strand cDNA synthesis 
was carried out from total RNA using AMV reverse 
transcriptase (Finnzymes) according to the manufacturer’s 
instructions. The primers for Q-RT-PCR were designed 
with Primer3 program.  SYBR Green II-Fast Start kit 
(Roche Diagnostics) and Light Cycler apparatus (Roche 
Diagnostics) were used for Q-RT-PCR. TBP (TATA box 
binding protein) and Actin mRNA was used as a reference. 
The specificity of the reactions was confirmed, in addition 
to the melting curve analysis, with 1.5% agarose gel 
electrophoresis.
Actin F- 5´- ACTTCACATCACAGCTCCCC -3´
Actin R- 5´- GAATATAATCCCAAGCGGTTTG -3´
TBP – F - 5´- 
CATAGGAATCCTTCTGACCCATG-3´
TBP R- 5´- 
CGAGCACAGAGCCTCGCCTTTGC-3´
CIP2A F- 5′-CTGGTGAGATAATCAGCAATTT-3′
CIP2A R- 
5′-CGAAACATTCATCAGACTTTTCA-3′
Small interfering RNA (siRNA) transfections
The siRNAs to inhibit CIP2A expression were 
obtained from Eurofins MWG operon (Ebersberg, 
Germany). The following double-stranded 
oligonucleotides were used:
CIP2A.1-5′-CUGUGGUUGUGUUUGCACUTT-3′
CIP2A.2-5′-ACCAUUGAUAUCCUU AGAATT-3′ 
AR.1(sense)-CCCAAGAUCCUUUCUGGGA+UU
AR.2 (sense)-GUGGAAGAUUCAGCCAAG 
C+UU
Scrambled-5′-UAACAAUGAGAGCACGGCTT-3 ′ 
Cells at 60%confluency were transfected with 
100nM in 3 mL of antibiotic free medium (RPMI-1640 
medium supplemented with 10% FCS) in each well 
with the respective siRNAs using Lipofectamine 2000 
Reagent (Life Technologies, Carlsbad, CA), according 
to the manufacturer’s instructions. For the primary PC 
cells (patient-derived prostate cancer cells, Gl-4+3), 
Cells at 70% confluency were transfected with 100nM 
of respective siRNA in 500 μL of Opti-MEM serum 
free medium (Life Technology) in each of the wells of 
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a 6-well plate using Oligofectamine (Life Technology). 
2mL of SCM was added after 4 hours in each well. After 
4 more hours, wells were washed with PBS twice and 2 
mL of fresh SCM was added. Cells were harvested at 72 
hours after transfection to determine the effect on protein 
expression.
Immunoflourescence
LNCaP-pcDNA3.1 and LNCaP-ARhi cells were 
seeded on sterilized coverslips placed in each well of a 
6-well plate overnight and the cells were then treated with 
1nM DHT for 24hours. Subsequently the cover slips were 
placed in fresh sterilized wells and then washed with PBS 
before being fixed using 4% paraformaldehyde for 10 min 
at 37° C. Then after washing with PBS twice, cells were 
treated with 0.5% NP-40 for 5min at room temperature. 
This was followed by blocking the cells with 0.5% bovine 
serum albumin for 30 min. Cells were then exposed to 
the following primary antibody dilutions, CIP2A; 1: 250 
(Santa Cruz Biotechnology, Santa Cruz, CA). After which 
the cells were washed with PBS 3 times and incubated 
in FITC-conjugated goat anti Rabbit IgG (Invitrogen–
Molecular Probes, Eugene, Oregon, USA) for 1h at 37°C. 
Next cells were then stained with the Vectashield antifade 
solution (Vector Laboratories) containing 0.001 mol/L 
4′,6-diamidino-2- phenylindole as counterstain and cells 
observed under the microscope and the images taken.
Chromatin immunoprecipitation (ChIP)
CIP2A ARBS was identified in previously published 
ChIP-seq dataset and ChIP was carried out as described 
before [25]. Chromatin was immunoprecipitated with 
10 µg of normal rabbit IgG, 10 µl of anti-AR polyclonal 
antibody (AR3). Primer sequences used for the CIP2A 
ARBS amplified via qPCR examined in this work are –
CIP2A Forward -5’ –
TTGTTCCTGGTCTTCCCTGT-3’, 
CIP2A Reverse -5’ –
GCAAAGTTTGATTGGTTTTTCC-3’
Immunohistochemistry
Mouse Anti-CIP2A (Novus Biosciences.) was used 
with Power Vision+ Poly-HRP IHC kit (ImmunoVision 
Technologies Co., Burlingame, CA, USA) according to the 
manufacturer’s instructions. The protocol has previously 
been described [18, 26].
Western blotting
Proteins were extracted in hot Laemmli sample 
buffer and subjected to Western blot analysis. 30 µg total 
protein extracts were separated by 12% SDS-PAGE and 
transferred to nitrocellulose membranes. Membranes 
were blocked with 5% non-fat milk in TBS-0.1%-NP40 
and then incubated with mouse monoclonal AR (AR441, 
NeoMarkers-Lab Vision Corporation, Fremont, CA, USA), 
goat polyclonal anti-β-Actin (Santa Cruz, Biotechnology, 
Santa Cruz, CA, USA) or with mouse monoclonal anti-
CIP2A (Santa Cruz Biotechnology, Santa Cruz, CA). For 
primary PC cells CytoBuster (Merck Millipore) buffer was 
used to lyse freshly cultured cells to extract proteins.
Cell viability
One day before transfection of CIP2A.1 or CIP2A.2 
siRNAs, LNCaP and LNCaP-ARhi cells were seeded in 
RPMI-1640 medium supplemented with 10% FCS at a 
density of 1 × 103 to 2 × 103 cells per well in 96-well 
plates. The cells were transfected with the following 
-Lipofectamine 2000 reagent, 33 nM scrambled siRNA 
or 33 nM CIP2A.1 or CIP2A.2. Cells were then cultured 
for 3 and 6 days post-transfection before relative numbers 
of viable cells were measured by fluorescence at the 
544 and 590 nm wavelengths in a FLUOstar OPTIMA 
Microplate Reader (BMG Labtech, Inc., Durham, NC), 
using the resazurin-based CellTiter-Blue Assay (Promega 
Corporation) according to the manufacturer’s instructions. 
In case of primary PC cells, 20µl of cell suspension was 
added to an equal volume of 0.4% Trypan Blue Stain 
(Sigma-Aldrich). The live cells were counted using 
modified Neubauer’s haemocytometer.
Soft agar and monolayer clonogenic assays
At 48 hours after transfection, LNCaP (1 × 104 
per dish) were suspended in 1 mL of 0.25% agarose 
(GellyPhor; EuroClone Spa, Pero, Italy) supplemented 
with 2 mL complete RPMI-1640 culture medium 
(changed every third day). This suspension was layered 
over 1 mL of a base layer of 0.5% agarose in complete 
medium in six-well plates. After 8 or 12 days in agarose, 
cells were stained with Giemsa 1:20 in water (Sigma-
Aldrich), the wells were scanned using the Surveyor 
Software (Objective Imaging Ltd.) with camera (Imaging 
Inc., Canada) attached to the Olympus IX71 (Olympus, 
Tokyo, Japan) microscope and colonies were counted by 
analysis with ImageJ Software (Wayne Rasband, National 
Institutes of Health, Betheseda, MD). Cell groupings 
that were greater than 1200 pixels in diameter with 
3.2× enlargements were counted as colonies. In case of 
primary PC cells, CIP2A and scrambled siRNAs were 
transfected into these cells for a day, after which they were 
trypsynised and 250 cells were plated in each well of the 
6-well Collagen-I coated plates (BD Biosciences). Cells 
were plated in triplicates with 2 ml of stem cell medium 
(SCM) and 500 µl of irradiated STO feeder cells per well. 
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The media was changed every 2-3 days. Clonal colonies 
were counted at the end of 12 days under a standard light 
microscope. For visualization, colonies were stained with 
crystal violet solution (Sigma-Aldrich).
Statistical analysis
The association between the CIP2A positivity in 
primary HN-PC, CRPC tumors and with AR expression 
was done using chi-square test. Kruskal-Wallis and student 
t-tests were used for other experiments. All statistical tests 
were two-sided.
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